FLT3 and acute myeloid leukemia: The approval of gilteritinib came from the ADMIRAL study, a multicenter, phase-3, randomized, placebo-controlled clinical trial of gilteritinib versus salvage chemotherapy for R/R AML patients with mutations in either FLT3-ITD, FLT3-TKD D835, or FLT3-TKD I836 [15].